Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
NCT07045727 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2026-03-30
Summary
This clinical trial evaluates whether prehabilitation with aerobic and resistance exercise improves physical fitness and quality of life outcomes in older patients planning to undergo chimeric antigen receptor (CAR)-T therapy for multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). CAR-T therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. Large numbers of the CAR-T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. While CAR-T therapy is commonly used to treat multiple myeloma, it can result in toxicities that lead to hospitalization, nerve and muscle impairment, and decreased physical function. Prehabilitation programs use targeted interventions to improve functional status prior to medical or surgical treatments. In this study, patients participate in personalized aerobic and resistance prehabilitation activities in the weeks leading up to their CAR-T infusion. This program may improve physical fitness and quality of life, both prior to and after CAR-T infusion, in older patients with relapsed or refractory multiple myeloma.
Conditions
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
Interventions
- PROCEDURE
-
Accelerometry
Ancillary studies
- OTHER
-
Aerobic Exercise
Participate in aerobic training program
- PROCEDURE
-
Biospecimen Collection
Undergo collection of blood and urine samples
- OTHER
-
Electronic Health Record Review
Ancillary studies
- OTHER
-
Exercise Counseling
Receive health coaching check-in calls
- OTHER
-
Internet-Based Intervention
Use Connected mHealth app
- OTHER
-
Interview
Ancillary studies
- OTHER
-
Physical Performance Testing
Ancillary studies
- OTHER
-
Resistance Training
Participate in resistance training program
- OTHER
-
Survey Administration
Ancillary studies
- PROCEDURE
-
Tailored Intervention
Receive personalized exercise plan
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Nadine H. Abdallah, MD · Mayo Clinic
-
Diane K. Ehlers, PhD · Mayo Clinic
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-08-18
- Primary Completion
- 2026-09-15
- Completion
- 2026-09-15
Countries
- United States
Study Locations
More Related Trials
-
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
NCT02597062 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT01936090 ·Status: COMPLETED ·Phase: PHASE1
-
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
NCT06630104 ·Status: RECRUITING ·Phase: NA
-
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
NCT02043860 ·Status: TERMINATED ·Phase: PHASE1
-
Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma
NCT00581919 ·Status: COMPLETED ·Phase: PHASE2
-
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
NCT05956457 ·Status: RECRUITING ·Phase: NA
-
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
NCT03100877 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
NCT01208662 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Autologous Transplant for Multiple Myeloma
NCT00177047 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
NCT02206425 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
NCT05276622 ·Status: TERMINATED
-
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05431608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
NCT03289299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
NCT00006219 ·Status: COMPLETED ·Phase: PHASE2
-
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
NCT02294357 ·Status: TERMINATED ·Phase: PHASE2
-
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
NCT01109407 ·Status: TERMINATED
-
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01665794 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
NCT01568866 ·Status: COMPLETED ·Phase: PHASE3
-
A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
NCT06559709 ·Status: COMPLETED ·Phase: NA
-
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02101944 ·Status: COMPLETED ·Phase: PHASE1
-
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
NCT01301807 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
NCT06149910 ·Status: RECRUITING
-
Personalized Autologous Transplant for Multiple Myeloma
NCT04483206 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
NCT03464916 ·Status: COMPLETED ·Phase: PHASE1